Tirzepatide is a relatively new drug that has been shown to have promising effects on glucose control, weight loss, and cardiovascular risk factors. It is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This combination makes it unique as most GLP-1 receptor agonist drugs do not activate GIP receptors, which can lead to a more complete response to glucose challenges.
Cardiometabolic Functional Medicine Information
Several recent studies have demonstrated the potential benefits of tirzepatide in reducing cardiovascular risk factors. One trial in particular, the SURPASS-4 study, published in The New England Journal of Medicine in 2021, evaluated the effects of tirzepatide on cardiovascular outcomes in adults with type 2 diabetes and established cardiovascular disease, or at high risk for it. The study found that tirzepatide significantly reduced major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, by 15% compared to placebo. Additionally, tirzepatide was associated with significant reductions in body weight, glycated hemoglobin levels, and blood pressure.
Another study published in Diabetes, Obesity, and Metabolism in 2021 evaluated the effects of tirzepatide on weight loss and glycemic control in adults with obesity and type 2 diabetes. The study found that tirzepatide was associated with significant reductions in body weight, body mass index, waist circumference, and glycated hemoglobin levels compared to placebo. The study further found that these effects on body weight were sustained over time, with patients continuing to experience weight loss at one year.
Tirzepatide is a promising addition to the treatment options for diabetes, particularly for patients with cardiovascular disease or at high risk for it. Its unique dual mechanism of action, combined with its demonstrated effects on weight loss, glycemic control, and blood pressure, make it a potentially powerful tool for managing both diabetes and its associated cardiovascular risks.
Dr. Christopher Davis, M.D. triple board-certified integrative concierge cardiologist and founder and C.E.O of Reveal Vitality in Sarasota, Florida believes that both tirzepatide and semaglutide offer effective cardioprotective and weight loss benefits safely for most clients. These drugs combined with personalized diet and exercise plans based on individual genetic and metabolic profiles can help clients look and feel their best and slow the aging process.
References:
- Bhatt DL, Szarek M, Steg PG, et al. Effect of Tirzepatide vs Placebo in Patients with Type 2 Diabetes and Increased Cardiovascular Risk: Results from the SURPASS-4 Randomized Clinical Trial. N Engl J Med. 2021 Apr 22;384(16):1508-1519. doi: 10.1056/NEJMoa210
